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COMMENT&RESPONSE
Oral FluoroquinoloneUse and Retinal Detachment
To the Editor We read with interest the recent article by
Raguideau et al1 on the association between the use of fluo-
roquinolone antibiotics and retinal detachment. The authors
chose to use 2 self-controlled study designs to address this
question: first, the case crossover method,2 and, second, the
self-controlledcase series.3The2methodsappear togive simi-
lar answers, suggesting a roughly 50% increased risk of reti-
naldetachment followingexposure toa fluoroquinolone.How-
ever,wehave someconcerns about themethodunderpinning
the study.
First, in the case-crossover study, Raguideau et al1 ex-
cluded peoplewhohad been exposed to any fluoroquinolone
during the intermediate-risk period, and they also excluded
all people exposed twice to a fluoroquinolonewithin any 50-
dayperiodduring the control period.Webelieve thismayhave
introduced an important bias, whereby people exposed dur-
ing the control periodwere disproportionately excluded. As a
consequence, patients would appear to be more likely ex-
posed during the risk period close to the date of retinal de-
tachment, potentially creating a spurious association.This ap-
proach is analogous to conducting a case-control study and
selecting patients based on prior knowledge of the exposure
of interest, which can cause serious bias. We note that 331 of
the 994 fluoroquinolone-exposed cases were excluded from
the main analysis for this reason, a substantial proportion
of the informative cases in this study. It would be helpful to
see the results of an analysis with no exclusions.
Second,a recentcohort study4withthesamequestionused
a“control” exposure todemonstrate that aneffect sizeof simi-
larmagnitudemay be driven by bias and confounding; the au-
thors found that fluoroquinolone and amoxicillin had similar
associationswith the riskof retinaldetachment.Althoughself-
controlleddesignsare less susceptible to individual-level time-
invariant confounding than traditional cohort studies, other
biases (in particular, indication bias) are not avoided, and a
similarcontrolexposure,nothypothesizedtobeassociatedwith
retinal detachment, would have been helpful in the study by
Raguideau et al1 to help exclude such biases.
Finally, the detailedmethods used for the self-controlled
case series arenotpresented in the studyor theonline supple-
mentary material. Correctly implementing this design re-
quires a careful choice of observation and risk periods.5 Is it
possible for the authors to provide further details on how the
self-controlled case-series analysis was performed? This ad-
ditional informationwould be helpful in the interpretation of
the conclusions.
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In ReplyOurmain analysis focusedon the immediate acute ef-
fects of fluoroquinolones.Therefore, as isusuallydone,weex-
cluded patients exposed during the intermediate risk period.
Because the intermediate risk period is not associatedwith an
increased risk, this exclusion is unlikely to have affected the
oddsratio. Individualswitha fluoroquinoloneprescriptiondur-
ing the 10 days preceding retinal detachment (RD) and ex-
posed during the intermediate risk period (ie, during the 50
prior days) were not considered exposed during the risk pe-
riod. Consistently, individuals with 2 fluoroquinolone pre-
scriptionsdispensedwithin50days in the control periodwere
not considered exposed either.
In a complementary analysis, we included the 331 pa-
tients exposed during the intermediate risk period. As antici-
pated, the results were unchanged; exposure to fluoroquino-
lones remained significantly associated with the occurrence
of RDduring the 10-day risk period,with an adjusted odds ra-
tio of 1.46 (95% CI, 1.17-1.81).
A potential confounding bias of the systemic disease for
which fluoroquinolonesmay be prescribed is possible. Other
studies1-5 previously managed this issue using another anti-
biotic as reference. The cohort study performed by Kuo et al2
reported, contrarily to the one performed by Daneman et al,1
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a significant association of fluoroquinolone usewith RD after
they compared the prescriptions of patients in the fluoroqui-
nolone cohortwith those of propensity score–matched adults
treated with amoxicillin. Moreover, the study design that we
usedensures theminimizationof confusionby indication. In-
deed, theself-matcheddesign implies that time-invariantmul-
tiplicative confounders arenecessarily adjusted for.Given the
short observation period of our study (180 days), the clinical
situations of the patients may be considered fixed during the
control and risk periods. Therefore, the prescription of fluo-
roquinolones for an underlying respiratory, inflammatory, or
infectiousdiseasemayoccur inanondifferentialmannerwithin
control or risk periods. In addition, in our study, we excluded
all patients who had been hospitalizedwithin 6months prior
to the RD. This likely resulted in excluding patients with se-
vere chronic diseases, including inflammatory diseases, and
thus minimizing confounding by indication. Lastly, to
control for potential residual bias, we conducted a sensitivity
analysis excluding patients with long-term infectious or in-
flammatory conditions and respiratory failure. Exposure to
fluoroquinolones remained significantly associated with the
occurrenceofRDover the 10-dayperiod,withanadjustedodds
ratio of 1.43 (95% CI, 1.11-1.84).
In the self-controlled case series design,we also looked at
first event, and we used the same short observation period.
Theriskperiodwasdefinedas the10-dayperiodaftereachfluo-
roquinolone prescription had been dispensed, whereas the
risk-freeperiod includedall other periodswhenpatientswere
considered to be at baseline risk. Individuals exposed to fluo-
roquinolones during the intermediate risk period (11-60days)
were excluded.
The incidence rate ratio and its 95%CIswere estimatedby
comparing the incidence of RD during the risk and risk-free
periods using a conditional Poisson regression model with a
logarithmic link function, taking the duration of the different
study periods into account. Given the study observation pe-
riod (180 days), age and comorbidities were considered to be
“fixed”during the studyperiod. Corticosteroid treatmentwas
taken into account as a time-dependent variable.
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